PolyNovo

Aging Populations Are Set To Expand Global Advanced Tissue Care

AnalystHighTarget

Not Invested

Community Contributor

Published

30 Jul 25

AnalystHighTarget's Fair Value

AU$2.65

47.2% undervalued

30 Jul

AU$1.40

-33.0%

4.9%

-33.0%

4.9%

You can edit this narrative until Jul 30 9:35 PM. Then, changes will post as Updates.

Author's Valuation

AU$2.6547.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$2.65

47.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.76%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.12%

Calculation

AU$53.68m

Earnings '28

41.81x

PE Ratio '28

AU$2.24b

Market Cap '28

AU$2.24b

Market Cap '28

690.84m

No. shares '28

AU$3.25

Share Price '28

AU$3.25 Share Price '28

Discounted to 2025 @ 7.07% p.a.

AU$2.65

Fair Value '25